Status: Not yet recruiting
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.
Participants needed: 1,212
Trial details
Phase: Phase 4Age: 30-80Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Jul 15, 2026Locations: 19
Eligibility criteria
Age 30 to 80 years, inclusive. [+3]
Intracranial arterial stenosis attributable to a nonatherosclerotic cause, such... [+13]